{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:31:48Z","timestamp":1761363108393,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jcv.2022.105165","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T13:04:57Z","timestamp":1650373497000},"page":"105165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Clinical performance of DNA and RNA based HPV tests for test of cure (TOC) post treatment for cervical intraepithelial neoplasia (CIN) - a retrospective study."],"prefix":"10.1016","volume":"150-151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5294-0668","authenticated-orcid":false,"given":"Ramya","family":"Bhatia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catriona","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Elasifer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Asodaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Moncur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Cuschieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcv.2022.105165_bib0001","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0140-6736(13)62218-7","article-title":"Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials","volume":"383","author":"Ronco","year":"2014","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.jcv.2022.105165_bib0002","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.currproblcancer.2018.06.013","article-title":"Update on primary HPV screening for cervical cancer prevention","volume":"42","author":"Rizzo","year":"2018","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.jcv.2022.105165_bib0003","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/610373","article-title":"The clinical role of HPV testing in primary and secondary cervical cancer screening","volume":"2013","author":"Hoste","year":"2013","journal-title":"Obstet. Gynecol. Int."},{"key":"10.1016\/j.jcv.2022.105165_bib0004","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bpobgyn.2017.08.002","article-title":"Role of HPV DNA testing in modern gynaecological practice","volume":"47","author":"Ronco","year":"2018","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"10.1016\/j.jcv.2022.105165_bib0005","first-page":"27","article-title":"Prediction of recurrent disease by cytology and HPV testing after treatment of cervical intraepithelial neoplasia","volume":"20","author":"Aerssens","year":"2009","journal-title":"Cytopathol. Off. J. Br. Soc. Clin. Cytol."},{"key":"10.1016\/j.jcv.2022.105165_bib0006","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/ajo.13115","article-title":"Compliance with follow-up test of cure and outcomes after treatment for high-grade cervical intraepithelial neoplasia in Victoria, Australia","volume":"60","author":"Tan","year":"2020","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"key":"10.1016\/j.jcv.2022.105165_bib0007","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ijc.24010","article-title":"Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older","volume":"124","author":"Meijer","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jcv.2022.105165_bib0008","doi-asserted-by":"crossref","first-page":"F88","DOI":"10.1016\/j.vaccine.2012.06.095","article-title":"Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer","volume":"30","author":"Arbyn","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.jcv.2022.105165_bib0009","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.jcv.2015.10.008","article-title":"HPV testing in the context of post-treatment follow up (test of cure)","volume":"76","author":"Cuschieri","year":"2016","journal-title":"J .Clin. Vir."},{"key":"10.1016\/j.jcv.2022.105165_bib0010","first-page":"1144","article-title":"Commercially available molecular tests for human papillomaviruses: a global overview","volume":"26","author":"Poljak","year":"2020","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.jcv.2022.105165_bib0011","doi-asserted-by":"crossref","unstructured":"Arbyn M., Snijders P.J.F., Meijer C.J.L.M., Berkhof J., Cuschieri K., Kocjan B.J., Poljak M. 2015. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin. Microbiol. Infect. Off. Publ. Eur. Soc. 10.1016\/j.cmi.2015.04.015.","DOI":"10.1016\/j.cmi.2015.04.015"},{"key":"10.1016\/j.jcv.2022.105165_bib0012","doi-asserted-by":"crossref","unstructured":"Arbyn M., Simon M., Peeters E., Meijer C.J.L.M., Berkhof J., Cuschieri K., Bonde J., O\u0161trbenk Valen\u010dak A., Zhao F.-.H., Rezhake R., Gultekin M., Dillner J., de Sanjos\u00e9 S., Canfell K., Hillemanns P., Almonte M., Xu L., Wentzensen N., Poljak M. 2021. 2020 List of human papillomavirus assays Suitable for primary cervical cancer screening. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. 10.1016\/j.cmi.2021.04.031.","DOI":"10.1016\/j.cmi.2021.04.031"},{"key":"10.1016\/j.jcv.2022.105165_bib0013","unstructured":"NHS Cervical Screening Programme Colposcopy and Programme Management 2016. NHSCSP 20 Colposcopy and Programme Management (3rd Edition) pdf (bsccp.org.uk)."},{"key":"10.1016\/j.jcv.2022.105165_bib0014","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1128\/JCM.00633-13","article-title":"Clinical validation of the abbott realtime high risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening","volume":"51","author":"Hesselink","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2022.105165_bib0015","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1128\/JCM.01517-13","article-title":"The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screening","volume":"51","author":"Heideman","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2022.105165_bib0016","doi-asserted-by":"crossref","first-page":"e01120","DOI":"10.1128\/JCM.01120-19","article-title":"Alinity m HR HPV assay fulfills criteria for human papillomavirus test requirements in cervical cancer screening settings","volume":"58","author":"O\u0161trbenk Valen\u010dak","year":"2019","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2022.105165_bib0017","unstructured":"Practical statistics for medical research. Douglas G. Altman, Chapman and Hall, London, 1991. No. of pages: 611. Price: \u00a332.00 - Ashby - 1991 - Statistics in Medicine - Wiley Online Library."},{"key":"10.1016\/j.jcv.2022.105165_bib0018","doi-asserted-by":"crossref","first-page":"e7086","DOI":"10.1136\/bmj.e7086","article-title":"Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS sentinel sites study","volume":"345","author":"Legood","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jcv.2022.105165_bib0019","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/LGT.0000000000000526","article-title":"A systematic review of tests for postcolposcopy and posttreatment surveillance","volume":"24","author":"Clarke","year":"2020","journal-title":"J. Low Genit. Tract. Dis."},{"key":"10.1016\/j.jcv.2022.105165_bib0020","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/jclinpath-2013-202014","article-title":"Evaluation of commercial HPV assays in the context of post-treatment follow-up: Scottish test of cure study (STOCS-H)","volume":"67","author":"Cubie","year":"2014","journal-title":"J. Clin. Pathol."},{"issue":"Suppl 1","key":"10.1016\/j.jcv.2022.105165_bib0021","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jcv.2015.09.014","article-title":"VALGENT: a protocol for clinical validation of human papillomavirus assays","volume":"76","author":"Arbyn","year":"2016","journal-title":"J. Clin. Virol. Off. Publ. Pan. Am. Soc. Clin. Virol."},{"key":"10.1016\/j.jcv.2022.105165_bib0022","unstructured":"Strang T.H.R., Gottschlich A., Cook D.A., Smith L.W., Gondara L., Franco E.L., van Niekerk D.J., Ogilvie G.S., Krajden M. 2021. Long-term cervical precancer outcomes after a negative DNA- or RNA-based human papillomavirus test result. Am. J. Obstet. Gynecol. S0002-9378(21)00606\u20132."},{"key":"10.1016\/j.jcv.2022.105165_bib0023","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jcv.2018.08.006","article-title":"VALHUDES: a protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples","volume":"107","author":"Arbyn","year":"2018","journal-title":"J. Clin. Virol. Off. Publ. Pan. Am. Soc. Clin. Virol."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653222000981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653222000981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T03:16:06Z","timestamp":1761362166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653222000981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":23,"alternative-id":["S1386653222000981"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2022.105165","relation":{},"ISSN":["1386-6532"],"issn-type":[{"type":"print","value":"1386-6532"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical performance of DNA and RNA based HPV tests for test of cure (TOC) post treatment for cervical intraepithelial neoplasia (CIN) - a retrospective study.","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2022.105165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105165"}}